X4 Pharmaceuticals Inc XFOR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences
-
X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
-
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024
-
X4 Pharmaceuticals Gets FDA Approval for Xolremdi Capsules
Trading Information
- Previous Close Price
- $0.61
- Day Range
- $0.61–0.65
- 52-Week Range
- $0.53–1.60
- Bid/Ask
- $0.60 / $0.64
- Market Cap
- $106.10 Mil
- Volume/Avg
- 760,792 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 222.98
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- 8.38%
Company Profile
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company’s lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 127
- Website
- https://www.x4pharma.com
Comparables
Valuation
|
Metric
|
XFOR
|
EXEL
|
VRDN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 17.20 | — |
Price/Book Value | 1.12 | 3.53 | 4.63 |
Price/Sales | 222.98 | 4.01 | 4,528.73 |
Price/Cash Flow | — | 16.42 | — |
Price/Earnings
XFOR
EXEL
VRDN
Financial Strength
|
Metric
|
XFOR
|
EXEL
|
VRDN
|
|---|---|---|---|
Quick Ratio | 5.87 | 4.05 | 15.54 |
Current Ratio | 6.07 | 4.27 | 15.82 |
Interest Coverage | 2.62 | — | −92.88 |
Quick Ratio
XFOR
EXEL
VRDN
Profitability
|
Metric
|
XFOR
|
EXEL
|
VRDN
|
|---|---|---|---|
Return on Assets (Normalized) | −70.73% | 14.82% | −34.35% |
Return on Equity (Normalized) | −205.05% | 19.05% | −64.16% |
Return on Invested Capital (Normalized) | −99.22% | 14.99% | −41.62% |
Return on Assets
XFOR
EXEL
VRDN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Kpncygxy | Glqc | $516.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Yddmhtmk | Ygqwy | $117.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ljpkddn | Myyvvf | $111.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xjsxwjgh | Slpps | $34.6 Bil | |||
| argenx SE ADR
ARGX
| Vvvlryq | Zlz | $33.0 Bil | |||
| BioNTech SE ADR
BNTX
| Klfwtvcx | Slsl | $28.5 Bil | |||
| Moderna Inc
MRNA
| Mtqdtqsy | Ylzg | $23.5 Bil | |||
| United Therapeutics Corp
UTHR
| Nymwbfrvt | Nsyt | $15.6 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Dyrglgvjh | Mmlbv | $13.0 Bil | |||
| Incyte Corp
INCY
| Xwbqqhpbb | Lpkcpb | $12.9 Bil |
United States